Corbus Pharmaceuticals Stock Price

-0.01 (-0.58%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Corbus Pharmaceuticals Holdings Inc CRBP NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.01 -0.58% 1.71 19:43:55
Open Price Low Price High Price Close Price Prev Close
1.68 1.63 1.80 1.64 1.72
Bid Price Ask Price Spread News
1.67 1.71 0.04 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
10,755 4,370,265 $ 1.68 $ 7,329,682 9,103,172 0.91 - 10.75
Last Trade Time Type Quantity Stock Price Currency
19:52:00 5 $ 1.71 USD

Corbus Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 143.70M 84.04M 68.54M $ 36.14M $ - -1.13 -1.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Corbus Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CRBP Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.84241.861.631.753,348,916-0.1324-7.19%
1 Month2.35822.391.631.913,443,087-0.6482-27.49%
3 Months2.154.001.632.6313,397,605-0.44-20.47%
6 Months1.10444.000.912.229,606,5240.605654.84%
1 Year5.8910.750.912.676,229,168-4.18-70.97%
3 Years6.8010.750.913.512,694,794-5.09-74.85%
5 Years2.3210.780.914.131,949,812-0.61-26.29%

Corbus Pharmaceuticals Description

Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

Your Recent History
Corbus Pha..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.